Michael Wolff Jensen

Conseiller Juridique Général chez ASCENDIS PHARMA A/S

Fortune : 264 412 $ au 30/04/2024

53 ans

92 relations

Health Technology

Utilities

Consumer Services

Relations actives

Nom	Sexe	Age	Sociétés liées	Collaboration
Jan Mikkelsen	M	65	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S Ascendis Pharma Endocrinology Division A/S Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. Ascendis Pharma Bone Diseases A/S Ascendis Pharma Growth Disorders AS VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	22 ans
Lotte Sønderbjerg	F	62	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	21 ans
An Bang Lu	M	58	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 ans
Albert Cha	M	51	ASCENDIS PHARMA A/S	10 ans
Peter Rasmussen	M	55	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	12 ans
Lisa Bright	F	56	ASCENDIS PHARMA A/S	7 ans
Yi Bo Cao	M	42	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction.	3 ans
Dan Dan Dong	M	40	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 ans
Kennett Sprogøe	M	46	ASCENDIS PHARMA A/S	17 ans
Rasmus Errboe	M	45	ORSTED A/S	12 ans
William Fairey	M	60	ASCENDIS PHARMA A/S	2 ans
Scott Smith	M	50	ASCENDIS PHARMA A/S	8 ans
Martine van Vugt	M	71	GENMAB A/S	23 ans
Lars Holtug	M	66	ASCENDIS PHARMA A/S	6 ans
Pierre Armand Morgon	M	61	EUROCINE VACCINES AB	11 ans
Carl-Johan Dalsgaard	M	68	Vicore Pharma AB Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden.	-
Hong Ni	F	52	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 ans
Peng Kuan Chan	M	60	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 ans
Zheng Bin Yao	M	58	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 ans
Siham Imani	F	47	ASCENDIS PHARMA A/S	2 ans
Shan Fu	M	56	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 ans
Heidi Hunter	F	66	VICORE PHARMA HOLDING AB	4 ans
Jan Nils Sandström	M	86	EUROCINE VACCINES AB	12 ans
Melinda Baker	F	-	ASCENDIS PHARMA A/S	-
Hans Jeppsson	M	-	Vicore Pharma AB Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden.	-
Sze Ting Chan	F	42	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	-
Elin Rosendahl	F	-	VICORE PHARMA HOLDING AB	4 ans
Birgitte Stephensen	F	63	GENMAB A/S	22 ans
Tim Lee	M	-	ASCENDIS PHARMA A/S	-
Anni Lotte Kirstine Pedersen	F	-	Ascendis Pharma Endocrinology Division A/S Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark.	12 ans
Jessica Shull	M	-	VICORE PHARMA HOLDING AB	3 ans
Stina Singel	M	50	ASCENDIS PHARMA A/S	4 ans
Maha Katabi	M	50	Ascendis Pharma, Inc.	-
Jun Yang	M	52	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	4 ans
Jun Chen	M	54	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 ans
Flemming Steen Jensen	M	63	ASCENDIS PHARMA A/S	9 ans

Graphique Relationnel

Relation dans plusieurs entreprises

Anciennes relations

Nom	Sexe	Age	Sociétés liées	Collaboration
Rafaèle Elisabeth Tordjman	M	54	ASCENDIS PHARMA A/S	13 ans
Thomas Soloway	M	55	ASCENDIS PHARMA A/S	5 ans
Birgitte Volck	M	61	ASCENDIS PHARMA A/S	7 ans
Michael Blair Widmer	M	76	GENMAB A/S	11 ans
Benny Dalgaard Loft	M	59	ORSTED A/S	7 ans
Anja Leschly	F	52	VELOXIS PHARMACEUTICALS A/S	-
Tom Vink	M	61	GENMAB A/S	-
Henrik Poulsen	M	57	ORSTED A/S	8 ans
Martin Olin	M	55	ASCENDIS PHARMA A/S	4 ans
Peter Schøtt Knudsen	M	51	VELOXIS PHARMACEUTICALS A/S	-
Michael Beckert	M	-	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	12 ans
Carsten Krogsgaard Thomsen	M	67	ORSTED A/S	11 ans
Bo Kruse	M	52	GENMAB A/S	8 ans
Pia Gjellerup	F	65	ORSTED A/S	7 ans
Jonathan Silverstein	M	57	ASCENDIS PHARMA A/S	-
James Healy	M	59	ASCENDIS PHARMA A/S	8 ans
Thomas Dyrberg	M	69	VELOXIS PHARMACEUTICALS A/S	13 ans
Kurt Anker Nielsen	M	78	VELOXIS PHARMACEUTICALS A/S	7 ans
Karsten Havkrog Pedersen	M	74	GENMAB A/S	11 ans
Thomas A. Larson	M	62	ASCENDIS PHARMA A/S	-
Kathrine Westermann	F	-	ORSTED A/S	-
Rasmus Nagel	M	-	ORSTED A/S	3 ans
Rikke Glahn Ren	F	-	GENMAB A/S	-
Dana Pizzuti	M	69	ASCENDIS PHARMA A/S	2 ans
Daniel Muthmann	M	-	ORSTED A/S	-
Jorgen Petersen	M	-	GENMAB A/S	-
Marie Olliver	M	-	EUROCINE VACCINES AB	-
Patrick van Berkel	M	55	GENMAB A/S	9 ans
Christina Aabo	F	-	ORSTED A/S	10 ans
Breian Knudsen	M	-	VELOXIS PHARMACEUTICALS A/S	9 ans
Mark Bach	M	67	ASCENDIS PHARMA A/S	-
Rune Róin	M	-	ORSTED A/S	-
Tomas Lykke Nielsen	M	-	ORSTED A/S	-
Sigurd Okkels	M	-	ASCENDIS PHARMA A/S	4 ans
Christian Skakkebæk	M	-	ORSTED A/S	10 ans
Gérard Soula	M	78	VELOXIS PHARMACEUTICALS A/S	-
Grethe Nørskov Rasmussen	M	62	ASCENDIS PHARMA A/S	11 ans
Jytte Koed Madsen	F	71	ORSTED A/S	-
Anders Eldrup	M	76	ORSTED A/S	11 ans
Jean Deleage	M	83	VELOXIS PHARMACEUTICALS A/S	-
Lars Rebien Sørensen	M	69	ORSTED A/S	5 ans
Martin Auster	M	49	ASCENDIS PHARMA A/S	2 ans
Mark Brennan	M	61	ASCENDIS PHARMA A/S	-
Torben Nissen	M	53	ASCENDIS PHARMA A/S	3 ans
Edwin de Graaf	M	-	ASCENDIS PHARMA A/S	-
Francesca DeMartino	F	-	VELOXIS PHARMACEUTICALS A/S	-
Jens Kampmann	M	86	ORSTED A/S	7 ans
Thomas Dalsgaard	M	58	ORSTED A/S	3 ans
Joseph Fred Yospe	M	66	GENMAB A/S	2 ans
Paul W. H. I. Parren	M	60	GENMAB A/S	16 ans
Lena Birgitta Degling Wikingsson	M	61	EUROCINE VACCINES AB	4 ans
Jonathan Leff	M	66	ASCENDIS PHARMA A/S	3 ans
Jesper Høiland	M	63	ASCENDIS PHARMA A/S	2 ans
Neil Ringdahl	M	-	ASCENDIS PHARMA A/S	-
Karsten Anker Petersen	M	53	ORSTED A/S	-
Niels Svenstrup	M	54	ASCENDIS PHARMA A/S	2 ans

Statistiques

Pays	Relations	% du total
Danemark	72	78,26%
Îles Cayman	11	11,96%
Suède	9	9,78%
Chine	5	5,43%
Etats-Unis	1	1,09%

Age des relations

Actives

Passées

Homme

Femme

Administrateurs

Exécutifs

Provenance des relations